Author:
Falzon Dennis,Schünemann Holger J.,Harausz Elizabeth,González-Angulo Licé,Lienhardt Christian,Jaramillo Ernesto,Weyer Karin
Abstract
Antimicrobial resistance is a major global concern. Tuberculosis (TB) strains resistant to rifampicin and other TB medicines challenge patient survival and public health. The World Health Organization (WHO) has published treatment guidelines for drug-resistant TB since 1997 and last updated them in 2016 based on reviews of aggregated and individual patient data from published and unpublished studies. An international expert panel formulated recommendations following the GRADE approach. The new WHO guidelines recommend a standardised 9–12 months shorter treatment regimen as first choice in patients with multidrug- or rifampicin-resistant TB (MDR/RR-TB) strains not resistant to fluoroquinolones or second-line injectable agents; resistance to these two classes of core second-line medicines is rapidly detectable with molecular diagnostics also approved by WHO in 2016. The composition of longer regimens for patients ineligible for the shorter regimen was modified. A first-ever meta-analysis of individual paediatric patient data allowed treatment recommendations for childhood MDR/RR-TB to be made. Delamanid is now also recommended in patients aged 6–17 years. Partial lung resection is a recommended option in MDR/RR-TB care. The 2016 revision highlighted the continued shortage of high-quality evidence and implementation research, and reiterated the need for clinical trials and best-practice studies to improve MDR/RR-TB patient treatment outcomes and strengthen policy.
Funder
United States Agency for International Development
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference67 articles.
1. General Assembly of the United Nations. High-level meeting on antimicrobial resistance. 2016. www.un.org/pga/71/2016/09/21/press-release-hl-meeting-on-antimicrobial-resistance Date last accessed: November 7, 2016.
2. Twenty years of global surveillance of antituberculosis-drug resistance;Zignol;N Engl J Med,2016
3. Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance
4. WHO. Guidelines for treatment of tuberculosis. 4th edn (WHO/HTM/TB/2009.420). 2009. http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf Date last accessed: November 7, 2016.
5. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Cited by
312 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献